We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+4.45%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$1.99B
AUM Growth
+$332M
(+20%)
Cap. Flow
+$245M
Cap. Flow
% of AUM
12.29%
Top 10 Holdings %
Top 10 Hldgs %
47.04%
Holding
78
New
21
Increased
16
Reduced
12
Closed
27
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$91M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$72.3M |
| 3 |
Agilent Technologies
A
|
+$56.1M |
| 4 |
Intuitive Surgical
ISRG
|
+$52.5M |
| 5 |
Danaher
DHR
|
+$50.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ENDP
Endo International plc
ENDP
|
+$52.2M |
| 2 |
Viatris
VTRS
|
+$43M |
| 3 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$32.9M |
| 4 |
Merck
MRK
|
+$32.4M |
| 5 |
Gilead Sciences
GILD
|
+$32.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 73.01% |
| 2 | Financials | 3.91% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MDRX
1
DELISTED
Veradigm Inc. Common Stock
MDRX
| $148M | 7.4% |
9,200,000
+800,000
| +10% | +$12.5M |
|
|
AGN
2
DELISTED
Allergan plc
AGN
| $112M | 5.59% |
500,000
+439,300
| +724% | +$91M |
|
|
MNK
3
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $104M | 5.22% |
1,300,000
+300,000
| +30% | +$21.7M |
|
|
WMGI
4
DELISTED
Wright Medical Group Inc
WMGI
| $98.9M | 4.96% |
3,150,000
+50,000
| +2% | +$1.49M |
|
|
5
Agilent Technologies
A
$39.2B
| $97.6M | 4.9% |
2,376,600
+1,398,000
| +143% | +$56.1M |
|
|
CBST
6
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
| $85.5M | 4.29% |
1,225,000
+500,000
| +69% | +$34M |
|
|
MDVN
7
DELISTED
MEDIVATION, INC.
MDVN
| $82.9M | 4.16% |
2,150,000
+150,000
| +8% | +$5.06M |
|
|
ALXN
8
DELISTED
Alexion Pharmaceuticals
ALXN
| $74.2M | 3.72% |
475,000
+457,700
| +2,646% | +$72.3M |
|
|
CFN
9
DELISTED
CAREFUSION CORPORATION
CFN
| $71M | 3.56% |
1,600,000
+600,000
| +60% | +$24.8M |
|
|
SLXP
10
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
| $64.8M | 3.25% |
525,000
-125,000
| -19% | -$13.8M |
|
11
eHealth
EHTH
$43.8M
| $61.7M | 3.09% |
1,625,000
| – | – |
|
|
12
Viatris
VTRS
$20.7B
| $60.6M | 3.04% |
1,175,000
-875,000
| -43% | -$43M |
|
|
13
Intuitive Surgical
ISRG
$126B
| $54.4M | 2.73% |
+1,189,800
| New | +$52.5M |
|
14
CALL
Vertex Pharmaceuticals
VRTX
$122B
| $53.7M | 2.69% |
+567,000
| New | +$39.8M |
|
15
McKesson
MCK
$101B
| $52.5M | 2.63% |
282,100
-67,900
| -19% | -$12.1M |
|
|
16
Danaher
DHR
$138B
| $51.6M | 2.59% |
+975,125
| New | +$50.1M |
|
|
NUVA
17
DELISTED
NuVasive, Inc.
NUVA
| $51.6M | 2.59% |
1,450,000
+450,000
| +45% | +$15.4M |
|
|
CTRX
18
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
| $50.1M | 2.51% |
1,133,500
+508,500
| +81% | +$21.5M |
|
19
HCA Healthcare
HCA
$85.7B
| $48.8M | 2.45% |
+864,900
| New | +$45.6M |
|
|
WBMD
20
DELISTED
WebMD Health Corp.
WBMD
| $47.1M | 2.36% |
975,000
-275,000
| -22% | -$12M |
|
|
TSRO
21
DELISTED
TESARO, Inc.
TSRO
| $45.9M | 2.3% |
1,475,000
+75,000
| +5% | +$2M |
|
|
HZNP
22
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $42.7M | 2.14% |
+2,700,000
| New | +$38.5M |
|
23
Jazz Pharmaceuticals
JAZZ
$16.2B
| $40.7M | 2.04% |
+277,000
| New | +$38.4M |
|
|
24
Gilead Sciences
GILD
$163B
| $37.1M | 1.86% |
447,600
-412,892
| -48% | -$32.1M |
|
25
Icon
ICLR
$12.8B
| $36.5M | 1.83% |
775,000
+340,600
| +78% | +$14.7M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q2 2014 Portfolio in Review
As of Q2 2014, HealthCor Management held 78 positions worth $1.99B, up 20% from $1.66B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
HealthCor Management deployed $245M of net new capital in Q2 2014, opening 21 new positions and adding to 16 existing holdings. Its largest new stake was Intuitive Surgical: 1,189,800 shares worth $54.4M.
By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 65% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Viatris, an estimated $43M trimmed.
- HealthCor Management's largest Q2 2014 buy was Intuitive Surgical: 1,189,800 shares worth $54.4M.
- HealthCor Management added most to Allergan plc in Q2 2014, an estimated $91M increase.
- HealthCor Management's biggest Q2 2014 reduction was Viatris, cutting an estimated $43M.
- HealthCor Management fully exited Endo International plc in Q2 2014, selling an estimated $52.2M.
- HealthCor Management's ten largest holdings make up 47% of its $1.99B portfolio in Q2 2014.
- HealthCor Management opened 21 new positions and closed 27 in Q2 2014.
- HealthCor Management's portfolio value rose 20% quarter-over-quarter to $1.99B.
Based on HealthCor Management's 13F filing for Q2 2014, filed 14 Aug 2014.